A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors
Ruijin Hospital
Ruijin Hospital
University Health Network, Toronto
Suzhou Genhouse Bio Co., Ltd.
M.D. Anderson Cancer Center
Cullgen (Shanghai),Inc
Xinqiao Hospital of Chongqing
Xinqiao Hospital of Chongqing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Mainline Biosciences (Shanghai) Co., Ltd
Gustave Roussy, Cancer Campus, Grand Paris
Roswell Park Cancer Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Medical University of South Carolina
Baylor College of Medicine
National University Hospital, Singapore
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shenzhen Geno-Immune Medical Institute
National Cancer Center, China
University Hospital, Antwerp
Jewish General Hospital
National University Hospital, Singapore
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NuCana plc
Shanghai Junshi Bioscience Co., Ltd.
Cancer Research UK
Tianjin Medical University Cancer Institute and Hospital
Shouyao Holdings (Beijing) Co. LTD
Guangzhou Sinogen Pharmaceutical Co., Ltd
Guangzhou Sinogen Pharmaceutical Co., Ltd
University Hospital, Antwerp
Rabin Medical Center
Memorial Sloan Kettering Cancer Center
Tianjin Medical University Second Hospital
University of California, San Francisco
Grupo Espanol de Investigacion en Sarcomas
China-Japan Friendship Hospital
Universitair Ziekenhuis Brussel
Shanghai Junshi Bioscience Co., Ltd.
University Hospital, Antwerp
Suzhou Genhouse Bio Co., Ltd.
Suzhou Genhouse Bio Co., Ltd.
Hunan Province Tumor Hospital
Memorial Sloan Kettering Cancer Center
Chinese PLA General Hospital
Capital Medical University
Sun Yat-sen University
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center